Paper4120640
Inhibition of respiratory virus infection by locally applied interferon.
Merigan TC and 3 others. Lancet, 1973. Cited by 151 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Inhibition of respiratory virus infection by locally applied interferon. Papers, record 4120640. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4120640
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Influenza, Human | Major topic |
| Interferons | Major topic |
| Respiratory Tract Infections | Major topic |
| Rhinovirus | Major topic |
| Virus Diseases | Major topic |
| Administration, Intranasal | |
| Antibodies, Viral | |
| Cells, Cultured | |
| Hemagglutination Inhibition Tests | |
| Humans | |
| Leukocytes | |
| Nasal Mucosa | |
| Neutralization Tests | |
| Organ Culture Techniques | |
| Orthomyxoviridae | |
| Placebos | |
| Trachea |
Source PubMed
Cited by75
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,515,322 | Pioneering Role of T.C. Merigan in the Treatment of Various Virus Infections. | Molecules | 2025 | https://conductscience.org/library/papers/41515322 | PubMed |
| 36,240,985 | Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities. | Pulm Pharmacol Ther | 2022 | https://conductscience.org/library/papers/36240985 | PubMed |
| 35,618,037 | Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019. | Eur J Pharmacol | 2022 | https://conductscience.org/library/papers/35618037 | PubMed |
| 35,387,044 | Review: The Nose as a Route for Therapy. Part 2 Immunotherapy. | Front Allergy | 2021 | https://conductscience.org/library/papers/35387044 | PubMed |
| 34,101,091 | Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β. | J Clin Immunol | 2021 | https://conductscience.org/library/papers/34101091 | PubMed |
| 32,665,127 | Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? | Cytokine Growth Factor Rev | 2020 | https://conductscience.org/library/papers/32665127 | PubMed |
| 32,287,580 | Chapter 7 Orthomyxovirus infections. | Perspect Med Virol | 1985 | https://conductscience.org/library/papers/32287580 | PubMed |
| 32,287,579 | Chapter 4 Picornavirus infections. | Perspect Med Virol | 1985 | https://conductscience.org/library/papers/32287579 | PubMed |
| 32,026,147 | Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. | World J Pediatr | 2020 | https://conductscience.org/library/papers/32026147 | PubMed |
| 27,713,254 | Oromucosal Administration of Interferon to Humans. | Pharmaceuticals (Basel) | 2010 | https://conductscience.org/library/papers/27713254 | PubMed |
| 27,713,234 | Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon. | Pharmaceuticals (Basel) | 2009 | https://conductscience.org/library/papers/27713234 | PubMed |
| 25,446,140 | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. | Adv Drug Deliv Rev | 2015 | https://conductscience.org/library/papers/25446140 | PubMed |
| 23,398,960 | Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. | Influenza Other Respir Viruses | 2013 | https://conductscience.org/library/papers/23398960 | PubMed |
| 21,152,181 | Treatment of hepatitis C infections with interferon: a historical perspective. | Hepat Res Treat | 2010 | https://conductscience.org/library/papers/21152181 | PubMed |
| 21,144,866 | Biodegradable nanogels for oral delivery of interferon for norovirus infection. | Antiviral Res | 2011 | https://conductscience.org/library/papers/21144866 | PubMed |
| 21,084,628 | The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. | J Leukoc Biol | 2011 | https://conductscience.org/library/papers/21084628 | PubMed |
| 18,611,565 | Biological response modifiers and infectious diseases: actual and potential therapeutic agents. | Int J Antimicrob Agents | 1994 | https://conductscience.org/library/papers/18611565 | PubMed |
| 18,070,219 | Clinical uses of interferons. | Br J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18070219 | PubMed |
| 18,049,472 | Interferons at age 50: past, current and future impact on biomedicine. | Nat Rev Drug Discov | 2007 | https://conductscience.org/library/papers/18049472 | PubMed |
| 15,737,415 | Development of rhinovirus study model using organ culture of turbinate mucosa. | J Virol Methods | 2005 | https://conductscience.org/library/papers/15737415 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4120640
GET https://conductscience.org/api/papers/v1/4120640/cited_by?page=2